Zibotentan-ZD4054-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEZibotentanCat. No.: HY-10088CAS No.: 186497-07-4Synonyms: ZD4054分式: CHNOS分量: 424.43作靶点: Endothelin Receptor作通路: GPCR/G Protein储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 25 mg/mL (58.90

2、 mM; Need ultrasonic)H2O : 90% corn oilSolubility: 2.5 mg/mL (5.89 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 Zibotentan (ZD4054)服活性的内素A（ETA）受体特异性拮抗剂，IC50为21 nM。REFERENCES1. Clarkson-Jones JA, Kenyon AS, Kemp J, Lenz EM, Oliver SD, Swaisland H.,Disposi

3、tion and metabolism of the specific endothelin Areceptor antagonist zibotentan (ZD4054) in healthy volunteers.,Xenobiotica. 2012 Apr;42(4):363-71. Epub 2011 Oct 20.2. Li J, Liu Y, Qian J, Wu L, Kemp J, Nii M, Tomkinson H, Zuo Y, Ranson M, Usami M.,Single- and multiple-dose pharmacokinetics, safetyan

4、d tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.,Cancer Chemother Pharmacol. 2012 Jul;70(1):57-63.Epub 2012 May 22.3. Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.,Phase 3, randomized,placebo-controlled study o

5、f zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.,Cancer. 2012 Jul11. doi: 10.1002/cncr.27674.4. Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T.,Pharmacokinetics and tolerability of zibotentan (ZD4054) insubjects with hepatic or renal impairment: two open-label comparative studies.,BMC Clin Pharmacol. 2011 Mar 17;11:3.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;